Skip to main content
TARS
NASDAQ Life Sciences

Tarsus Q2 XDEMVY Sales Surge 69% to $174M, Raises 2026 Guidance to $705M, Acquires Alkeus

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$58.56
Mkt Cap
$2.637B
52W Low
$40.55
52W High
$85.25
52W Position info
44% above low
Off High info
31% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

TARS sits 44% above its 52-week low of $40.55 on light trading volume (0.4× avg).

Summary

Tarsus delivered a standout quarter with XDEMVY net sales of $173.9M, up 69% year-over-year, driven by volume and better gross-to-net. Full-year guidance was raised to $685-705M, signaling confidence in continued commercial momentum. The company also announced the acquisition of Alkeus Pharmaceuticals for up to $800 million, adding a Phase 3 program for Stargardt disease, and priced a $125M private placement to fund the deal. These moves follow the recent iRenix acquisition and CCO departure, showing aggressive pipeline expansion and commercial execution. The Alkeus deal and raised guidance materially shift the growth outlook, with multiple catalysts ahead including Phase 2 data for TP-04 and TP-05 in H1 2027.

Updates

  1. · SEC 8-K — The 8-K details 2,098,519 shares at $56.00 and 133,625 pre-funded warrants at $55.9999, with closing expected August 7, 2026.

  2. · SEC 8-K — The 8-K specifies $270M cash and $180M stock upfront, up to $350M in milestones, and low-to-mid single digit royalties on gildeuretinol sales.

At the time of this announcement, TARS was trading at $58.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $40.55 to $85.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

TARS - Latest Insights

TARS
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $74.00
Real-time Price: $78.20 info
Change: +$4.20 (+6%) info
Market Cap: $3.856B info
TARS
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $71.24
Real-time Price: $78.20 info
Change: +$6.96 (+10%) info
Market Cap: $3.856B info
TARS
Oct 13, 2026, 4:00 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $70.82
Real-time Price: $78.20 info
Change: +$7.38 (+10%) info
Market Cap: $3.856B info
TARS
Sep 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $81.12
Real-time Price: $78.20 info
Change: -$2.92 (-4%) info
Market Cap: $3.856B info
TARS
Aug 06, 2026, 7:25 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $58.27
Real-time Price: $78.20 info
Change: +$19.93 (+34%) info
Market Cap: $3.856B info